118 related articles for article (PubMed ID: 8112308)
21. Invariant chain cleavage and peptide loading in major histocompatibility complex class II vesicles.
Amigorena S; Webster P; Drake J; Newcomb J; Cresswell P; Mellman I
J Exp Med; 1995 May; 181(5):1729-41. PubMed ID: 7722451
[TBL] [Abstract][Full Text] [Related]
22. A lysosomal targeting signal in the cytoplasmic tail of the beta chain directs HLA-DM to MHC class II compartments.
Marks MS; Roche PA; van Donselaar E; Woodruff L; Peters PJ; Bonifacino JS
J Cell Biol; 1995 Oct; 131(2):351-69. PubMed ID: 7593164
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of invariant chain (Ii)-calnexin interaction results in enhanced degradation of Ii but does not prevent the assembly of alpha beta Ii complexes.
Romagnoli P; Germain RN
J Exp Med; 1995 Dec; 182(6):2027-36. PubMed ID: 7500048
[TBL] [Abstract][Full Text] [Related]
24. Invariant chain made in Escherichia coli has an exposed N-terminal segment that blocks antigen binding to HLA-DR1 and a trimeric C-terminal segment that binds empty HLA-DR1.
Park SJ; Sadegh-Nasseri S; Wiley DC
Proc Natl Acad Sci U S A; 1995 Nov; 92(24):11289-93. PubMed ID: 7479981
[TBL] [Abstract][Full Text] [Related]
25. Association with BiP and aggregation of class II MHC molecules synthesized in the absence of invariant chain.
Bonnerot C; Marks MS; Cosson P; Robertson EJ; Bikoff EK; Germain RN; Bonifacino JS
EMBO J; 1994 Feb; 13(4):934-44. PubMed ID: 8112308
[TBL] [Abstract][Full Text] [Related]
26. Transient aggregation of major histocompatibility complex class II chains during assembly in normal spleen cells.
Marks MS; Germain RN; Bonifacino JS
J Biol Chem; 1995 May; 270(18):10475-81. PubMed ID: 7737982
[TBL] [Abstract][Full Text] [Related]
27. The invariant chain is required for intracellular transport and function of major histocompatibility complex class II molecules.
Elliott EA; Drake JR; Amigorena S; Elsemore J; Webster P; Mellman I; Flavell RA
J Exp Med; 1994 Feb; 179(2):681-94. PubMed ID: 8294875
[TBL] [Abstract][Full Text] [Related]
28. BiP and immunoglobulin light chain cooperate to control the folding of heavy chain and ensure the fidelity of immunoglobulin assembly.
Lee YK; Brewer JW; Hellman R; Hendershot LM
Mol Biol Cell; 1999 Jul; 10(7):2209-19. PubMed ID: 10397760
[TBL] [Abstract][Full Text] [Related]
29. Assembly and secretion of heavy chains that do not associate posttranslationally with immunoglobulin heavy chain-binding protein.
Hendershot L; Bole D; Köhler G; Kearney JF
J Cell Biol; 1987 Mar; 104(3):761-7. PubMed ID: 3102505
[TBL] [Abstract][Full Text] [Related]
30. Posttranslational association of immunoglobulin heavy chain binding protein with nascent heavy chains in nonsecreting and secreting hybridomas.
Bole DG; Hendershot LM; Kearney JF
J Cell Biol; 1986 May; 102(5):1558-66. PubMed ID: 3084497
[TBL] [Abstract][Full Text] [Related]
31. A method for determining the sedimentation behavior of enzymes: application to protein mixtures.
MARTIN RG; AMES BN
J Biol Chem; 1961 May; 236():1372-9. PubMed ID: 13767412
[No Abstract] [Full Text] [Related]
32. Peptide binding inhibits protein aggregation of invariant-chain free class II dimers and promotes surface expression of occupied molecules.
Germain RN; Rinker AG
Nature; 1993 Jun; 363(6431):725-8. PubMed ID: 8515815
[TBL] [Abstract][Full Text] [Related]
33. Interaction with newly synthesized and retained proteins in the endoplasmic reticulum suggests a chaperone function for human integral membrane protein IP90 (calnexin).
David V; Hochstenbach F; Rajagopalan S; Brenner MB
J Biol Chem; 1993 May; 268(13):9585-92. PubMed ID: 8486646
[TBL] [Abstract][Full Text] [Related]
34. Relationship between invariant chain expression and major histocompatibility complex class II transport into early and late endocytic compartments.
Romagnoli P; Layet C; Yewdell J; Bakke O; Germain RN
J Exp Med; 1993 Mar; 177(3):583-96. PubMed ID: 8436902
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
